May 2005
Volume 46, Issue 13
ARVO Annual Meeting Abstract  |   May 2005
Aqueous Humor Concentrations of Fourth Generation Fluoroquinolone in Humans
Author Affiliations & Notes
  • J.D. Aronowicz
    Ophthalmology, UT Southwestern Med Ctr, Dallas, TX
  • W. Shine
    Ophthalmology, UT Southwestern Med Ctr, Dallas, TX
  • J.P. McCulley
    Ophthalmology, UT Southwestern Med Ctr, Dallas, TX
  • Footnotes
    Commercial Relationships  J.D. Aronowicz, None; W. Shine, None; J.P. McCulley, Alcon Laboratories F, C, R.
  • Footnotes
    Support  RPB unrestricted grant
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 5051. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J.D. Aronowicz, W. Shine, J.P. McCulley; Aqueous Humor Concentrations of Fourth Generation Fluoroquinolone in Humans . Invest. Ophthalmol. Vis. Sci. 2005;46(13):5051.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To determine the aqueous humor concentration of two commercial fourth generation fluoroquinolones, moxifloxacin and gatifloxacin, after q.i.d. dosing in humans undergoing planned phacoemulsification and IOL insertion.Methods: In this ongoing study, forty–six human eyes without associated ocular disease undergoing phacoemulsification and IOL insertion, were dosed with one drop q.i.d. one day before surgery and one hour prior to planned entry of the anterior chamber on the day of surgery. Aqueous humor samples were collected, frozen and subsequently analyzed by HPLC to determine the concentration of the fluoroquinolone in the aqueous humor. All participants were masked throughout the investigative process.Results: Interim results indicate the aqueous humor concentrations achieved after the topical application of the two commercial preparations, i.e., VigamoxTM containing moxifloxacin and ZymarTM containing gatifloxacin, were as follows: moxifloxacin 1.86 ± 0.23 gms/ml and gatifloxacin 0.95 ± 0.15 gms/ml (p = 0.001).Conclusions: Moxifloxacin in the commercial preparation, VigamoxTM, resulted in a statistically significant greater penetration of fourth generation fluoroquinolone into the aqueous humor compared to gatifloxacin in commercial Zymar. Moxifloxacin reaches a Cmax which is 10X the MIC of the bacteria most frequently causing postoperative endophthalmitis.

Keywords: antibiotics/antifungals/antiparasitics • pharmacology • endophthalmitis 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.